Investigator's choice of therapy

DRUG2 trials

Sponsors

Zai Lab (Shanghai) Co., Ltd., Innovent Biologics (Suzhou) Co. Ltd.

Conditions

Colorectal CancerSmall-cell Lung Cancer

Phase 3

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

RecruitingNCT07218146

Zai Lab (Shanghai) Co., Ltd.Small-cell Lung Cancer

Start: 2025-11-30End: 2028-11-30Target: 480Updated: 2026-09-14

IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer

RecruitingNCT07722494

Innovent Biologics (Suzhou) Co. Ltd.Colorectal Cancer

Start: 2026-07-31End: 2030-12-31Target: 550Updated: 2026-08-10

Related Papers

A randomized, open-label, phase 3 study of ZL-1310, a DLL3 antibody-drug conjugate (ADC), compared to investigator’s choice therapy in participants with relapsed small cell lung cancer (DLLEVATE).

Journal of Clinical Oncology2026-05-28